314 results on '"Maetens, Marion"'
Search Results
2. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
3. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review
4. Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
5. Reporting on invasive lobular breast cancer in clinical trials: a systematic review
6. Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer
7. Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor–Positive/HER2 Negative Metastatic Breast Cancer
8. Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium
9. Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases
10. Obesity-associated changes in molecular biology of primary breast cancer
11. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer
12. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer
13. Timing evolution of lobular breast cancer through phylogenetic analysis
14. The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
15. Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology
16. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer:a systematic review
17. Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
18. Reporting on invasive lobular breast cancer in clinical trials: a systematic review
19. Digital analysis of distant and cancer-associated mammary adipocytes
20. Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
21. Research autopsy programmes in oncology: shared experience from 14 centres across the world
22. Abstract A004: Comparison of ctDNA detection in seven different types of body liquids from patients with metastatic breast cancer
23. Data from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
24. Supplementary Figure 12 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
25. TABLE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
26. FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
27. Supplementary Figure 6 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
28. FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
29. Supplementary Figure 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
30. FIGURE 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
31. Supplementary Figure 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
32. Supplementary Table 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
33. FIGURE 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
34. Supplementary Table 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
35. Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
36. Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
37. Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
38. Supplementary Table 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
39. Supplementary Figure 7 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
40. Supplementary Figure 8 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
41. FIGURE 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
42. Treatment response, tumor infiltrating lymphocytes and clinical outcomes in inflammatory breast cancer treated with neoadjuvant systemic therapy
43. Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases
44. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
45. Obesity-associated changes in molecular biology of primary breast cancer.
46. CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial
47. Table S1, S2, S3, S4 from Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
48. Figure S3 from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
49. Supplementary Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
50. Table S5 from Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.